NICE Recommends Biosimilars Ahead of Remicade

from HealthEconomics.Com at on June 29, 2015 at 04:55PM

NICE has recommended two new biosimilar versions of Remicade, Inflectra and Remsima, and says these new treatments should be used ahead of the original patented medicine. Final draft guidance on the subject is expected to be published in October. Read more here. (Source: Ben Adams, PMLiVE, 6/22/15)